Cargando…
The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer
In the era of precision medicine, oncological imaging techniques are advancing at a rapid pace, particularly molecular imaging with promising new targets for prostate cancer (PC) such as gastrin releasing peptide receptors (GRPR) along the established and indispensable prostate specific membrane ant...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441085/ https://www.ncbi.nlm.nih.gov/pubmed/36057766 http://dx.doi.org/10.1186/s40644-022-00481-3 |
_version_ | 1784782501011521536 |
---|---|
author | Duan, Heying Iagaru, Andrei |
author_facet | Duan, Heying Iagaru, Andrei |
author_sort | Duan, Heying |
collection | PubMed |
description | In the era of precision medicine, oncological imaging techniques are advancing at a rapid pace, particularly molecular imaging with promising new targets for prostate cancer (PC) such as gastrin releasing peptide receptors (GRPR) along the established and indispensable prostate specific membrane antigen (PSMA). As PC is characterized by heterogenous tumor biology ranging from indolent to aggressive disease, distinguishing clinically significant tumors from indolent disease is critical. Multiparametric MRI- and PET-targeted prostate biopsies mitigate the shortcomings and risks of standard systematic template biopsy by identifying more significant cancers. Focal treatment for localized disease is a minimally invasive approach that targets the index tumor – the lesion of the highest grade – while sparing the surrounding healthy tissue. Real-time MRI-guidance and thermal control with MR-thermometry, improves treatment accuracy and results in lower rates of functional side effects. PET imaging could be an useful tool to assess response to treatment compared to invasive prostate biopsies. In this comprehensive review, we focus on the image-guided detection and treatment of localized primary prostate cancer, its current status and future perspectives. |
format | Online Article Text |
id | pubmed-9441085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94410852022-09-05 The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer Duan, Heying Iagaru, Andrei Cancer Imaging Review In the era of precision medicine, oncological imaging techniques are advancing at a rapid pace, particularly molecular imaging with promising new targets for prostate cancer (PC) such as gastrin releasing peptide receptors (GRPR) along the established and indispensable prostate specific membrane antigen (PSMA). As PC is characterized by heterogenous tumor biology ranging from indolent to aggressive disease, distinguishing clinically significant tumors from indolent disease is critical. Multiparametric MRI- and PET-targeted prostate biopsies mitigate the shortcomings and risks of standard systematic template biopsy by identifying more significant cancers. Focal treatment for localized disease is a minimally invasive approach that targets the index tumor – the lesion of the highest grade – while sparing the surrounding healthy tissue. Real-time MRI-guidance and thermal control with MR-thermometry, improves treatment accuracy and results in lower rates of functional side effects. PET imaging could be an useful tool to assess response to treatment compared to invasive prostate biopsies. In this comprehensive review, we focus on the image-guided detection and treatment of localized primary prostate cancer, its current status and future perspectives. BioMed Central 2022-09-03 /pmc/articles/PMC9441085/ /pubmed/36057766 http://dx.doi.org/10.1186/s40644-022-00481-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Duan, Heying Iagaru, Andrei The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer |
title | The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer |
title_full | The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer |
title_fullStr | The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer |
title_full_unstemmed | The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer |
title_short | The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer |
title_sort | use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441085/ https://www.ncbi.nlm.nih.gov/pubmed/36057766 http://dx.doi.org/10.1186/s40644-022-00481-3 |
work_keys_str_mv | AT duanheying theuseofadvancedimaginginguidingthefurtherinvestigationandtreatmentofprimaryprostatecancer AT iagaruandrei theuseofadvancedimaginginguidingthefurtherinvestigationandtreatmentofprimaryprostatecancer AT duanheying useofadvancedimaginginguidingthefurtherinvestigationandtreatmentofprimaryprostatecancer AT iagaruandrei useofadvancedimaginginguidingthefurtherinvestigationandtreatmentofprimaryprostatecancer |